Skip to main content
Hit enter to search or ESC to close
Close Search
Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact
twitter
facebook
linkedin
Investors
Press Releases
NASDAQ: ENVB
Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Press Releases
Enveric Biosciences Receives Notice of Allowance From USPTO for C4-Carboxylic Acid-Substituted Tryptamine Derivatives for Next Generation Psilocin Prodrug
May 24, 2023
Enveric Biosciences Announces Manuscript Detailing the Development of Novel Psilocin Prodrugs for the Treatment of Anxiety and Other Mental Health Disorders
May 22, 2023
Enveric Biosciences to Participate in 2023 BIO International Convention in Boston
May 19, 2023
Enveric Biosciences Receives Notice of Allowance from USPTO for Novel Prodrug of Psilocin
May 18, 2023
Enveric Biosciences Reports First Quarter 2023 Financial Results and Operational Highlights
May 15, 2023
Enveric Biosciences Celebrates and Supports 2023 Mental Health Awareness Month
May 2, 2023
Enveric Biosciences to Participate in Benzinga Psychedelics Capital Conference
April 10, 2023
Enveric Biosciences Reports Fourth Quarter and Year-End 2022 Corporate and Financial Results
April 3, 2023
Enveric Biosciences Selects Australian CRO, Avance Clinical, in Preparation for Phase 1 Study of EB-373
March 23, 2023
Enveric Biosciences Establishes Australia-based Subsidiary to Accelerate its Lead Psilocin Prodrug Program Targeting Mental Health Indications
March 21, 2023
‹
1
…
3
4
5
6
7
…
12
›
Close Menu
Company
Team
Psybrary™
Pipeline
Investors
Investor Overview
Press Releases
Media Coverage
Events + Presentations
Stock Information
SEC Filings
Corporate Governance
News Alerts
Contact